Theratechnologies’ Targeted Oncology Technology Positive Results From Theratechnologies Targeted Oncology Technology Presented On-Line at ASCO GlobeNewswireMay 16, 2019, 7:30 AM EDT MONTREAL, May 16, 2019 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (Theratechnologies) (TH.TO) is pleased to announce that positive results from in vivo and in vitro research, using its specific Sortilin receptor platform for the treatment of triple-negative breast cancer and ovarian cancer, were published on-line in two abstracts as part of the American Society of Clinical Oncology (ASCO) annual conference. Theratechnologies new oncology technology, a conjugate of docetaxel and a Sortilin-targeting peptide, was tested in vitro and in vivo in triple-negative breast cancer (TNBC) models. Docetaxel is commonly used for the treatment of various types of cancers. Results demonstrate that the Docetaxel-peptide conjugate triggered faster and higher cell death mechanisms in vitro than did Docetaxel alone and showed greater tumor regression capacity with a prolonged survival in a murine MDA-MB-231 xenograft tumor model in vivo. In both arms, the conjugate was demonstrated to be specifically internalized through a receptor-mediated mechanism. To test the efficacy of this new technology in ovarian cancer, Doxorubicin was conjugated to the same Sortilin-targeting peptide. Doxorubicin is a cytotoxic agent commonly used for the treatment of ovarian cancer. The conjugate was assessed in vivo and in vitro. In vitro, uptake of the conjugate was assessed in ES-2 and SKOV-3 ovarian cancer cell lines. In a different experiment, the Sortilin gene was specifically silenced to determine if the uptake of the conjugate would then be reduced. Results show uptake of the conjugate in both Sortilin-positive cell lines and a reduction of the uptake when Sortilin expression was specifically silenced. In vivo, the conjugate demonstrated potential to reduce side-effects compared to Doxorubicin alone due to lower accumulation in healthy tissues such as the heart and ovary. The conjugate also caused a more potent inhibition of human ovarian tumor xenografts growth and was better tolerated (absence of leukopenia and neutropenia) than Doxorubicin alone. Story continues Start the conversation Sign in to post a message. What to Read Next On the radar: Nissan stays cool on lidar tech, siding with Tesla Reuters Montrals Secret Bars: Our Three Hidden Gems Porter Sponsored 3 Top Energy Stocks to Buy Right Now Motley Fool Universal Display Turns Its Attention to Investment In OLED Technology Motley Fool Why ImmunoGen Shares Are Crashing Today Motley Fool 3 Ways to Know Your Tires are Safe to Ride on Michelin Sponsored 5G Stocks To Invest In Span Chipmakers Qualcomm And Xilinx, Corning, Verizon Investor's Business Daily Walmart beats on earnings, posts best Q1 comp sales in 9 years Yahoo Finance The Midwest's Most Successful Software Entrepreneur Sets His Sights on Healthcare Motley Fool Not a recent condition, how about 3500+ years ago! Canada Protection Plan Sponsored Guggenheim: ZG 'Building Comfort' In Offers Business Yahoo Finance Video Guggenheim gets bullish on Zillow's Offers business Yahoo Finance Georgetown to expel student after he sues over its handling of college admissions probe USA TODAY Step Forward into the Future Ford Canada Sponsored Trump order clears way for barring Huawei from U.S. telecommunications networks Reuters Leaked audio: Pilots grill Boeing officials between deadly 737 MAX crashes Yahoo Finance Johnson & Johnson to submit applications for at least 10 new drugs by 2023 Reuters Plenty O' Fish Out There (40+) Mature Quality Singles Sponsored